Welcome to our dedicated page for Oruka Therapeutics SEC filings (Ticker: ORKA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Oruka Therapeutics, Inc. (NASDAQ: ORKA) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures, including current reports, financial statements, and material agreements. As a Nasdaq-listed clinical-stage biotechnology company focused on biologic therapies for chronic skin diseases, Oruka uses its SEC filings to report key corporate, financial, and governance information related to its psoriasis and inflammatory disease programs.
Investors can review Form 8-K current reports where Oruka describes material events such as private placement financings, changes in directors and executive officers, and the terms of securities purchase agreements and registration rights agreements. These filings also document board appointments, committee roles, director compensation, and equity awards, providing detail on corporate governance and leadership transitions.
Periodic reports such as Form 10-Q and Form 10-K (when available) contain condensed consolidated financial statements, including research and development and general and administrative expenses, net losses, cash, cash equivalents, and marketable securities. For a clinical-stage company like Oruka, these filings help readers understand the level of investment in plaque psoriasis and other dermatologic programs, as well as the company’s capital position and runway assumptions.
Stock Titan enhances these filings with AI-powered summaries that highlight the most important points, such as trial-related disclosures, financing structures, and changes in share count. Users can also access information related to equity issuances and warrant terms, and track how Oruka’s capital structure evolves over time. Real-time updates from EDGAR ensure that new ORKA filings, including any future proxy statements or insider transaction reports on Form 4, appear promptly with plain-language explanations to support more efficient review.
Oruka Therapeutics director Carl Dambkowski reported a mix of stock sales and option exercises in Oruka Therapeutics, Inc. common stock. On May 21, 2026, he sold a total of 105,000 shares in open‑market transactions at weighted average prices around $58–$60 per share under a pre‑arranged Rule 10b5‑1 trading plan. On the same date, he exercised stock options and warrants covering 62,260 shares at exercise prices of $6.84, $7.80, and $11.77 per share, converting derivative awards into common stock. He continues to hold unexercised options and warrants that expire between 2034 and 2035.
ORKA-related securities holder submitted a Form 144 proposing sales of common stock totaling 105,000 shares. The filing lists two transactions: 62,260 shares tied to an Exercise of Stock Options dated 05/21/2026 and 42,740 shares from a Partnership Distribution dated 02/14/2024. The sales are described as cash transactions.
Oruka Therapeutics, Inc. Senior Vice President, Finance Arjun Agarwal reported a mix of stock option exercises and share sales in Oruka common stock. On May 18, 2026, he exercised 7,833 employee stock options at exercise prices of $34.39 and $12.50 per share, converting derivative awards into common shares. The same day, he sold 10,290 common shares in open-market transactions under a pre-arranged Rule 10b5-1 trading plan, at weighted average prices spanning approximately $57.72 to $61.76 per share. This pattern reflects routine option exercise paired with partial share sales for liquidity under a pre-planned program.
ORKA reported proposed sales of common stock by insiders under multiple mechanisms. The notice lists 19,749 shares from an exercise of stock options dated 05/18/2026, 1,758 shares from the Employee Stock Purchase Plan dated 12/08/2025, and 699 shares issuable upon Restricted Stock Units dated 03/14/2026.
The filing also records a prior sale of 395 shares by Arjun Agarwal on 03/16/2026 for $16,313.50.
Oruka Therapeutics, Inc.’s Chief Medical Officer, Joana Goncalves, reported option exercises and related share sales. On May 15, 2026, she exercised options and warrants to acquire a total of 7,000 shares of common stock at exercise prices of $7.80 and $6.84 per share. On the same date, she sold an aggregate 7,000 common shares in open-market transactions at weighted-average prices of about $61.56, $62.42 and $63.52 per share pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025. Following these transactions, she directly owned 33,377 shares of Oruka Therapeutics common stock.
Oruka Therapeutics, Inc. Schedule 13G/A Amendment No. 1 reports that Viking Global Investors and affiliated entities beneficially own 2,666,690 shares of Common Stock, representing 5.3% of the class, effective March 31, 2026. The filing removes David C. Ott as a reporting person due to his retirement.
The filing states the 2,666,690 shares comprise 1,600,014 shares held by Viking Global Opportunities entities and 1,066,676 shares held by Viking Global Opportunities Drawdown entities. Shares outstanding are listed as 50,167,623 as of March 31, 2026.
Oruka Therapeutics, Inc. reported a net loss of $31.8 million for the three months ended March 31, 2026, reflecting increased investment in its psoriasis and inflammatory disease pipeline. Research and development expenses rose to $29.1 million and general and administrative expenses to $7.3 million, driven by higher clinical activity, headcount and stock-based compensation.
The company held $496.0 million in cash, cash equivalents and marketable securities as of March 31, 2026 and later strengthened liquidity with $38.9 million of at-the-market share sales and a subsequent underwritten offering raising gross proceeds of $700.4 million. Lead antibodies ORKA-001 and ORKA-002 advanced through Phase 1 and Phase 2 studies, with ORKA-001 showing high rates of complete skin clearance in psoriasis and ORKA-002 moving into mid-stage trials in psoriasis and planned trials in hidradenitis suppurativa.
Fairmount-affiliated funds filed Amendment No. 5 to their Schedule 13D on Oruka Therapeutics, Inc. to disclose a new lock-up agreement while keeping their reported ownership unchanged. Fairmount Funds Management LLC and related entities report beneficial ownership of 13,665,080 shares of common stock, representing 19.99% of Oruka’s common stock based on 68,359,627 shares outstanding as of April 30, 2026.
The position includes common shares and shares issuable upon conversion of Series B non-voting convertible preferred stock, subject to a 19.99% beneficial ownership limitation. Additional 5,297,664 warrant shares and 1,468,331 shares issuable from Series B preferred are excluded because of 9.99% and 19.99% ownership caps.
In connection with Oruka’s underwritten public offering that closed on April 30, 2026, the reporting persons entered into a customary lock-up letter with the underwriters, agreeing not to sell company securities for 45 calendar days from the date of the underwriting agreement, unless Leerink Partners consents. They did not purchase securities or otherwise participate in the offering.
Oruka Therapeutics, Inc. Chief Operating Officer Laura Lee Sandler reported multiple transactions in the company’s common stock. On May 1, 2026, she completed open-market sales totaling 5,000 shares at weighted average prices within ranges from $62.33 to $67.20 per share under a pre-established Rule 10b5-1 trading plan.
On the same date, she also exercised employee warrants to acquire 5,000 shares of common stock at an exercise price of $7.80 per share. The warrant covers 5,000 underlying shares, vests over time beginning April 3, 2025, and is scheduled to expire on July 14, 2034.
Laura Sandler submitted a Form 144 notice to sell 10,000 shares of Common stock on 05/01/2026. The filing lists the proposed sale as resulting from an Exercise of Stock Options with cash consideration. The record also shows prior 10b5-1 sales of 5,000 shares for $167,821.50 on 03/02/2026 and 600 shares for $24,780.00 on 03/16/2026.